Select Page

COMPANY HISTORY Bind Therapeutics was launched in 2007 as Bind Biosciences with the vision of revolutionizing the treatment of life-threatening diseases through the application of nanotechnology. After two decades of research at MIT in the area of biomaterials and nanoparticle engineering, a number of critical technologies converged in the laboratory of Professor Robert Langer that would enable the development of therapeutic polymeric nanoparticles. Building on this convergence, Professor Omid Farokhzad of Harvard Medical School began collaborating with Professor Langer to apply combinatorial strategies to develop targeted nanoparticles for specific therapeutic applications. This research, conducted in collaboration with the Koch Institute at MIT and Brigham and Women’s Hospital-Harvard Medical School resulted in a the development of the Medicinal Nanoengineering platform, which enables the identification of the precise characteristics of an optimally engineered targeted nanoparticle for clinical applications. The company was cofounded by Drs. Langer and Farokhzad for the purpose of developing and commercializing innovative and impactful pharmaceutical products based on the medicinal nanoengineering platform. Bind Biosciences was launched with an initial financing round from Flagship Ventures and Polaris Partners. The company now occupies 33,000 square feet of lab and office space in Cambridge. Bind Russia, a wholly owned subsidiary, was established in October 2011 to access the scientific experience and clinical trial resources in Russia, enabling full-cycle drug development—from R&D through commercialization. In 2013, the company changed its name to Bind Therapeutics to reflect its progress in developing a pipeline of Accurins based on the Medicinal Nanoengineering platform.]]>